In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers.

M. A. Pfaller, A. L. Barry, L. D. Sabath, B. N. Kreiswirth, P. R. Murray, P. C. Fuchs, J. C. McLaughlin

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

The in vitro activity of ceftriaxone and six additional antimicrobial agents (ceftizoxime, cefoperazone, cefuroxime, fleroxacin, ciprofloxacin, and trimethoprim/sulfamethoxazole) was assessed or 602 recent clinical isolates of staphylococci from six geographically distinct medical centers in North America. All seven antimicrobial agents were active (90-100% of strains susceptible) against oxacillin-susceptible (OS) strains of Staphylococcus aureus (OSSA) and coagulase-negative staphylococci (OSCNS) but had limited activity against oxacillin resistant (OR) staphylococci. Our assessment of the in vitro antistaphylococcal activity of ceftriaxone against contemporary isolates of Staphylococcus aureus and coagulase-negative staphylococci indicates that the activity versus OS staphylococci has not changed over the past decade despite widespread use of the drug. It appears that these agents will continue to be useful for empiric therapy in those centers in which OR strains are uncommon.
Original languageUndefined/Unknown
Pages (from-to)658-662
Number of pages5
JournalEuropean Journal of Epidemiology
Volume9
Issue number6
StatePublished - 1993

Keywords

  • Academic Medical Centers
  • Ceftriaxone/pd [Pharmacology]
  • Cephalosporins/pd [Pharmacology]
  • Humans
  • In Vitro Techniques
  • Microbial Sensitivity Tests
  • Staphylococcal Infections/ep [Epidemiology]
  • Staphylococcal Infections/mi [Microbiology]
  • Staphylococcus aureus/de [Drug Effects]
  • Staphylococcus aureus/ip [Isolation & Purification]
  • United States/ep [Epidemiology]

Cite this

Pfaller, M. A., Barry, A. L., Sabath, L. D., Kreiswirth, B. N., Murray, P. R., Fuchs, P. C., & McLaughlin, J. C. (1993). In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers. European Journal of Epidemiology, 9(6), 658-662.